Hello. It's great to see all of you. You know, once a year I get the benefit of thanking all of you for the incredible work that you do.As you know, we pioneered a new way of doing computing called accelerated computing. And we've been working on this for now 33 years. The big idea, the big idea is that if you could co-design, meaning if you understood the problems you're trying to compute for, and you developed the entire stack, meaning the algorithms, the computers, and the processors within it that if yo ...

Thank you. Thank you for that elaborate introduction. There are moments when the world holds its breath all together.COVID was one of them. In early 2020, cities went silent, borders closed, and uncertainty was global. While the crisis was shared, the choices were not.Not all the nations had the same access, the same resources, and certainly not the same margin for error. For some nations, the question was how fast science could move. For some other nations, the question was whether survival could afford sc ...

Core Viewpoint - Regeneron Pharmaceuticals reported strong fourth-quarter earnings, exceeding market expectations in both earnings per share and sales figures [1][3]. Financial Performance - The company posted adjusted earnings of $11.44 per share, a decrease of 5% year-over-year, but above the consensus estimate of $10.71 [1]. - Sales reached $3.88 billion, reflecting a 3% year-over-year increase, surpassing the consensus of $3.79 billion [1]. Future Projections - For fiscal 2026, Regeneron anticipates a GAAP gross margin of 79%–80% and an adjusted gross margin of 83%–84% [2]. - The company forecasts adjusted R&D expenses between $5.9 billion and $6.1 billion, with non-GAAP SG&A expenditures projected to be between $2.5 billion and $2.65 billion [2]. Market Reaction - Following the earnings announcement, Regeneron shares increased by 2.1%, trading at $756.63 [3]. - Analysts have adjusted their price targets for Regeneron Pharmaceuticals in response to the earnings report [3].

Core Viewpoint - Regeneron Pharmaceuticals reported strong fourth-quarter earnings, exceeding market expectations in both earnings per share and sales figures [1][3]. Financial Performance - The company posted adjusted earnings of $11.44 per share, a decrease of 5% year-over-year, but above the consensus estimate of $10.71 [1]. - Sales reached $3.88 billion, reflecting a 3% year-over-year increase, surpassing the consensus of $3.79 billion [1]. Future Projections - For fiscal 2026, Regeneron anticipates a GAAP gross margin of 79%–80% and an adjusted gross margin of 83%–84% [2]. - The company forecasts adjusted R&D expenses between $5.9 billion and $6.1 billion, with non-GAAP SG&A expenditures projected to be between $2.5 billion and $2.65 billion [2]. Market Reaction - Following the earnings announcement, Regeneron shares increased by 2.1%, trading at $756.63 [3]. - Analysts have adjusted their price targets for Regeneron Pharmaceuticals in light of the earnings report [3].

Core Insights - Ultragenyx Pharmaceutical (RARE) has resubmitted its biologics license application (BLA) to the FDA for accelerated approval of its gene therapy candidate UX111, aimed at treating Sanfilippo syndrome type A (MPS IIIA) [1][8] - The company’s shares have decreased by 44.6% over the past year, contrasting with a 15.2% increase in the industry [2] BLA Resubmission Details - The FDA issued a Complete Response Letter (CRL) in July 2025, requesting additional information regarding chemistry, manufacturing, and controls (CMC) elements, which were facility- and process-related issues not tied to product quality [3][10] - The resubmitted BLA addresses all CMC observations from the CRL and includes long-term data supporting neurological benefits, along with biomarker data in line with FDA agreements [4][11] Regulatory Timeline - A target action date from the FDA is expected within a month, with a review period of up to six months anticipated, aiming for a decision in the third quarter of 2026 [5][8] Clinical Data and Efficacy - The original BLA submission was supported by data from the phase I/II/III Transpher A study, which showed that UX111 treatment led to a significant reduction in heparan sulfate (HS) levels in cerebrospinal fluid (CSF) and improved long-term cognitive development [9][11] - The updated clinical data in the resubmission includes an additional year of patient follow-up, demonstrating durable treatment benefits and increasing separation from untreated outcomes [11] Disease Context - Sanfilippo syndrome type A is a rare, fatal lysosomal storage disorder affecting the central nervous system, with approximately 3,000 to 5,000 patients in commercially accessible areas and a median life expectancy of 15 years [14]

Core Insights - AstraZeneca (AZN) has entered a strategic collaboration with CSPC Pharmaceutical to develop next-generation therapies for obesity and type 2 diabetes (T2D) [1][2] Group 1: Deal Overview - AstraZeneca aims to secure exclusive worldwide rights (outside China) to CSPC's once-monthly injectable weight-management pipeline, which includes a near-clinical asset, SYH2082, and three other preclinical programs [2][8] - The deal encompasses eight programs, with AstraZeneca and CSPC advancing four programs using CSPC's AI-driven peptide drug discovery platform and proprietary LiquidGel technology [3][7] - AstraZeneca will make an upfront payment of $1.2 billion to CSPC, with potential milestone payments of up to $3.5 billion across all eight programs [5][7] Group 2: Development and Commercialization - CSPC will continue developing the four programs through phase I, after which AstraZeneca will take over further development and commercialization outside China [8] - CSPC retains rights in China, Taiwan, Hong Kong, and Macau, while AstraZeneca has an option to co-commercialize the products in these markets upon potential approval [8] Group 3: Strategic Investments - This collaboration follows AstraZeneca's recent announcement of a $15 billion investment to expand manufacturing and R&D capabilities in China through 2030 [9] - The investment supports AstraZeneca's strategic ambitions to achieve total revenues of $80 billion by 2030 and launch 20 new medicines, with several expected to exceed peak annual revenues of $5 billion [10] Group 4: Competitive Landscape - The obesity market is currently dominated by Eli Lilly and Novo Nordisk, with both companies generating significant revenues from their cardiometabolic drugs [11] - Novo Nordisk recently launched an oral version of its Wegovy pill, while an FDA decision for Lilly's oral obesity pill is expected in the first half of 2026 [12] - Other companies, including Viking Therapeutics, are also developing treatments for obesity, indicating a growing interest in this lucrative market [13]

Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per share on revenue of $16.12 billion, representing 3.1% year-over-year growth. Shares have gained 13% over the past year, outperforming the healthcare sector's broader returns. Here's what investors should watch for. This infographic outlines Wall Street's expectations for MRK's Q4 2025 earnings report on February 3, 2026, alongside analyst price targets and historical beat rates. The N ...

Core Viewpoint - The stock of Aquestive Therapeutics, Inc. (AQST) has surged approximately 43% following the announcement of a Complete Response Letter (CRL) from the FDA regarding its New Drug Application for Anaphylm Sublingual Film, aimed at treating Type I allergic reactions [1]. Stock Performance - AQST is currently trading at $4.22, reflecting a 42.98% increase from the previous close of $2.95. The stock opened at $3.79 and reached a high of $4.39 during the trading session. Over the past year, the stock has fluctuated between $2.12 and $7.55 [2]. Future Plans - The company intends to request a Type A meeting with the FDA to discuss the most efficient path for resubmission of the application. Based on an initial review of the CRL, the company estimates that resubmission will occur in the third quarter of 2026. Additionally, the company plans to request a rapid review by the FDA [3].

Core Viewpoint - AbbVie is expected to report fourth-quarter and full-year 2025 earnings on February 4, with sales projected at $16.36 billion and earnings per share (EPS) at $2.66, although EPS estimates for 2025 and 2026 have declined recently [2][6]. Earnings Performance - AbbVie has consistently exceeded earnings expectations in the past four quarters, with an average earnings surprise of 3.05%, including a 5.08% surprise in the last quarter [4][6]. Revenue Drivers - The anticipated revenue growth for AbbVie in Q4 2025 is primarily driven by increased sales of newer immunology drugs, Skyrizi and Rinvoq, as sales of the flagship drug Humira continue to decline due to biosimilar competition [9][10]. - The Zacks Consensus Estimate for Skyrizi sales is $4.91 billion, while Rinvoq is estimated at $2.39 billion [9]. Sales Estimates - Humira's sales are projected at $949 million, reflecting ongoing erosion from biosimilars, while Imbruvica sales are expected to decline to $715 million due to competition [10]. - Sales for Roche-partnered Venclexta are estimated to rise to $725 million, driven by strong demand [11]. - Neuroscience product sales are expected to reach approximately $3.00 billion, supported by strong performances from Botox Therapeutic, Vraylar, and new migraine drugs [12]. - Aesthetics product sales are projected at $1.28 billion, showing signs of recovery from previous sluggishness [13]. Valuation and Market Position - AbbVie shares are currently trading at a P/E ratio of 15.38, below the industry average of 18.42, indicating a discount relative to peers [17]. - Despite underperforming the industry over the past year, AbbVie is expected to achieve robust revenue growth driven by its newer drug launches [19]. Future Outlook - AbbVie anticipates a high single-digit revenue compound annual growth rate (CAGR) through 2029, supported by the successful launches of Skyrizi and Rinvoq [19]. - The company continues to invest in its pipeline through strategic collaborations, including a recent licensing deal with RemeGen for a bispecific antibody candidate [21]. - A favorable valuation and strong earnings growth expectations provide a compelling case for long-term investment in AbbVie stock [22].

Core Insights - Novo Nordisk's experimental weight-loss drug CagriSema demonstrated superior efficacy in reducing blood sugar levels and body weight compared to semaglutide alone in a late-stage trial involving patients with type 2 diabetes [1] Group 1 - CagriSema is a next-generation weight-loss drug developed by Novo Nordisk [1] - The late-stage trial focused on patients diagnosed with type 2 diabetes [1] - Results indicated that CagriSema outperformed semaglutide in both blood sugar reduction and weight loss [1]